Popup

You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go Back

Go to Close Top

Synflorix UMV: recommended by more and more national and local public health authorities 1-8

The use of Synflorix is supported by an increasing number of national and local public health authorities.

In 2018, 39 countries worldwide included Synflorix in their UMV/NIP programs.9

Here’s what some of them reported in support of their decision making:

More information on Synflorix here

References:

  1. Pharmacology and Therapeutics Advisory Committee (PTAC) [New Zealand]. Immunisation Subcommittee of PTAC. Meeting held 28 October 2015 (minutes for web publishing). Available at: https://www.pharmac.govt.nz/assets/ptac-immunisation-subcommittee-minutes-2015-10.pdf [accessed May 2018].
  2. Superior Health Council of Belgium (Conseil Supérieur de la Santé). Avis du Conseil Supérieur de la Santé Nº 8813. [Vaccination of children and adolescents against pneumococcus]; May 2015. Available at: https://www.vaccination-info.be/assets/files/CSSpneumoenfants2015.pdf [accessed May 2018].
  3. Health Council of the Netherlands. Executive summary. Vaccination of infants against pneumococcal infections; 2013. Available at: https://www.gezondheidsraad.nl/sites/default/files/summary_Vaccinatie_zuigelingen_tegen_pneumokokkeninfecties_3.pdf [accessed May 2018].
  4. Conseil Supérieur des Maladies Infectieuses (CSMI) [Superior Health Council of Infectious Diseases, Luxembourg]. [CSMI opinion for universal pneumococcal vaccination: 10 or 13-valent vaccine?]; September 20, 2016. Available at: http://www.sante.public.lu/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/infection-pneumocoques/2016-09-20-vaccination-pneumocoque.pdf [accessed May 2018].
  5. National Institute for Health and Welfare (Terveyden ja hyvinvoinnin laitos; THL) [Finland]. Tendering process for pneumococcal conjugate vaccine. Available at: http://en.opasnet.org/w/Tendering_process_for_pneumococcal_conjugate_vaccine[accessed May 2018].
  6. Polskiego Towarzystwa Wakcynologii [Polish Society of Vaccinology]. [Position of the Board of the Polish Society of Vaccinology of 30/01/2017 on the selection of a vaccine for the general free vaccination of children against pneumococcus in Poland under the Protective Vaccination Programme]. Available at: http://ptwakc.org.pl/aktualnosci/stanowisko-zarzadu-polskiego-towarzystwa-wakcynologii-30-01-2017-r-sprawie-wyboru-szczepionki-powszechnego-bezplatnego-szczepienia-dzieci-przeciwko-pneumokokom-polsce-ramach-programu/ [accessed May 2018].
  7. Institut national de santé publique du Québec (INSPQ) [National Institute of Public Health of Quebec, Canada]. [Opinion on the optimal timing of vaccination of children against pneumococcal disease in Quebec]; September 2017. Available at: https://www.inspq.qc.ca/sites/default/files/publications/2334_calendrier_vaccination_enfants_infections_pneumocoque.pdf [accessed May 2018].
  8. Ministerio de Salud [Ministry of Health, El Salvador]. [Twitter tweet]; March 17, 2018. Available at: https://twitter.com/minsalud/status/974762737795588096/photo/1?ref_src=twsrc%5Etfw&ref_url=http%3A%2F%2Felmundo.sv%2Fminsal-confirma-cambio-de-vacuna-contra-el-neumococo%2F [accessed June 2018].
  9. GSK Data on File 2018N371700_00

The flags depicted in this material is for generalized illustration only.Whilst all efforts have been made to ensure the accuracy of the national flags of the respective countries depicted in this material, however GSK and its directors do not own any responsibility for the correctness or authenticity of the same

Synflorix is a registered trademark of the GlaxoSmithKline Group of Companies. For the use of Registered Medical Practitioners.

Please report adverse events with any GSK products to the company at india.pharmacovigilance@gsk.com.